Popular
INSM · Medicine & biotech · U.S.

Insmed

Makes medicines for serious lung diseases.

Company Health

30
/100
Weak
A quick check of the business from its yearly reports (2022–2025). It doesn’t say whether the stock is a good buy.
Does it make money?
0 of 25 · Poor
It lost money last year: $211 of every $100 in sales.
Is it growing?
25 of 25 · Good
Sales grew about 35% a year over the last 3 years.
Can it handle what it owes?
5 of 25 · Poor
Its business used cash last year, and it owes $67 of every $100 it owns.
Does it bring in spare cash?
0 of 25 · Poor
It spent more cash than it brought in: $160 of every $100 in sales.

Who owns it

1 of 23 own it · 1 bought more lately
bought lately
owns it
doesn’t own it
Didn’t report owning it: Whale Rock, Appaloosa, Melqart, Coatue, D1 Capital, Light Street, Lone Pine, Third Point, TCI, Pershing Square, Himalaya Capital, Greenlight, Giverny Capital, Fundsmith, Semper Augustus, Akre
Their letters don’t mention it: Arquitos, Laughing Water, Alluvial, Bireme, Kingdom Capital, Saga Partners
From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

The numbers

From Insmed’s yearly reports. Tap a year to see its figures.

Sales and profit

Sales grew from $164 million in 2020 to $606 million in 2025, and it lost money every year.
2025
Sales
$606 million
Loss
$1.28 billion

Spare cash each year

It spent more cash than it brought in every year: $968 million more in 2025.
2025
Cash shortfall
$968 million
Spare cash is the cash its business brought in, minus what it spent on buildings and equipment.

What it owns and what it owes

At the end of 2025 it owned $2.26 billion, including $510 million in cash, and owed $1.53 billion.

Key facts

From its yearly report for 2025.
Sales
$606 million
Loss
$1.28 billion
Cash shortfall
$968 million
Cash in the bank
$510 million
Everything it owes
$1.53 billion
Year ends
December
Money shown in
U.S. dollars
Latest yearly report
10-K, filed Feb 19, 2026
Figures from Insmed’s yearly reports to the SEC (EDGAR), collected Oct 12, 2026.
Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works
Privacy policy